Herwig P Moll

List of Publications by Year
in descending order

28	876	623699	501174
papers	citations	14 h-index	28 g-index

32	32	32	1840
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The glucocorticoid receptor associates with RAS complexes to inhibit cell proliferation and tumor growth. Science Signaling, 2022, 15, eabm4452.	3.6	11
2	A20/TNFAIP3 Increases ENOS Expression in an ERK5/KLF2-Dependent Manner to Support Endothelial Cell Health in the Face of Inflammation. Frontiers in Cardiovascular Medicine, 2021, 8, 651230.	2.4	8
3	Down-regulation of A20 promotes immune escape of lung adenocarcinomas. Science Translational Medicine, 2021, 13, .	12.4	10
4	STAT3: Versatile Functions in Non-Small Cell Lung Cancer. Cancers, 2020, 12, 1107.	3.7	60
5	Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future. International Journal of Molecular Sciences, 2020, 21, 4325.	4.1	84
6	IDO1+ Paneth cells promote immune escape of colorectal cancer. Communications Biology, 2020, 3, 252.	4.4	26
7	JAKâ€“STAT inhibition impairs Kâ€RASâ€driven lung adenocarcinoma progression. International Journal of Cancer, 2019, 145, 3376-3388.	5.1	54
8	A Mouse Model to Assess STAT3 and STAT5A/B Combined Inhibition in Health and Disease Conditions. Cancers, 2019, 11, 1226.	3.7	3
9	MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. Nature Genetics, 2019, 51, 990-998.	21.4	61
10	Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression. Journal of Visualized Experiments, 2019, , .	0.3	4
11	Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. Journal of Clinical Investigation, 2019, 130, 612-624.	8.2	27
12	STAT3Î² is a tumor suppressor in acute myeloid leukemia. Blood Advances, 2019, 3, 1989-2002.	5.2	20
13	<scp>AKT</scp>3 drives adenoid cystic carcinoma development in salivary glands. Cancer Medicine, 2018, 7, 445-453.	2.8	13
14	Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis. Molecular and Cellular Oncology, 2018, 5, e1513724.	0.7	2
15	Afatinib restrains K-RASâ€“driven lung tumorigenesis. Science Translational Medicine, 2018, 10, .	12.4	99
16	A20 Haploinsufficiency Aggravates Transplant Arteriosclerosis in Mouse Vascular Allografts. Transplantation, 2016, 100, e106-e116.	1.0	7
17	Unexpected oncosuppressive role for STAT3 in KRAS-induced lung tumorigenesis. Molecular and Cellular Oncology, 2016, 3, e1036199.	0.7	3
18	Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nature Communications, 2015, 6, 6285.	12.8	124

#	Article	IF	Citations
19	A20 suppresses vascular inflammation by recruiting proinflammatory signaling molecules to intracellular aggresomes. FASEB Journal, 2015, 29, 1869-1878.	0.5	13
20	Heterologous protein production using euchromatin-containing expression vectors in mammalian cells. Nucleic Acids Research, 2015, 43, e102-e102.	14.5	46
21	A20 Regulates Atherogenic Interferon (IFN)-Î³ Signaling in Vascular Cells by Modulating Basal IFNÎ² Levels. Journal of Biological Chemistry, 2014, 289, 30912-30924.	3.4	20
22	A20 deficiency causes spontaneous neuroinflammation in mice. Journal of Neuroinflammation, 2014, 11, 122.	7.2	53
23	Anti-Viral Tetris: Modulation of the Innate Anti-Viral Immune Response by A20. Advances in Experimental Medicine and Biology, 2014, 809, 49-64.	1.6	12
24	Translational Studies of A20 in Atherosclerosis and Cardiovascular Disease. Advances in Experimental Medicine and Biology, 2014, 809, 83-101.	1.6	8
25	The C-terminal domain of A1/Bfl-1 regulates its anti-inflammatory function in human endothelial cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1553-1561.	4.1	4
26	A20-Mediated Modulation of Inflammatory and Immune Responses in Aortic Allografts and Development of Transplant Arteriosclerosis. Transplantation, 2012, 93, 373-382.	1.0	26
27	The differential activity of interferon-Î± subtypes is consistent among distinct target genes and cell types. Cytokine, 2011, 53, 52-59.	3.2	75
28	Contamination with recombinant IFN accounts for the unexpected stimulatory properties of commonly used IFNâ€blocking antibodies. European Journal of Immunology, 2011, 41, 252-254.	2.9	2